(Updated to correct Cell Therapeutics share price.)
NEW YORK (TheStreet) -- Several stocks trading near $5 were poised to move on above-average volume during Thursday's session.
EnteroMedics (ERTM) surged by 52 cents, or 64.2%, to $1.33 in early trading after the company said its Maestro System continues to meet its safety goals, according to data from weight loss, hypertension and diabetes clinical studies. The 50-day average daily volume for is 856,000, according to the Nasdaq.
Atlantic Bancgroup (ATBC) slumped by 55 cents, or 15.5%, to $3 after the company said in a regulatory filing late Wednesday that is has consented to the issuance of a consent order with the Federal Deposit Insurance Corporation and the Florida Office of Financial Regulation. Atlantic Bancgroup said it entered into the consent order without admitting or denying any charges of unsafe or unsound banking practices or violations of law or regulation. The 50-day average daily volume for Atlantic Bancgroup is 4,500.Cell Therapeutics (CTIC) fell by 13 cents, or 9.7%, to $1.21 at the open after the company said it raised $30 million through the sale of preferred stock and warrants. The 50-day average daily volume for Cell Therapeutics is 10.61 million shares. Bionovo (BNVI) rose by 8 cents, or 12.9%, to 70 cents in early trading after the company announced the publication of their results from its phase 1B clinical trial of Bezielle (BZL101) for metastatic breast cancer in Breast Cancer Research and Treatment. The results show that "Bezielle continues to be safe and well tolerated with clinical evidence of anticancer activity" in a heavily pretreated population of women diagnosed with metastatic breast cancer. The 50-day average daily volume for Bionovo is 1.28 million.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV